Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-cL blocking agents in rheumatoid arthritis

M. Benucci, M. Manfredi, G. Saviola, P. Baiardi, P. Campi

Research output: Contribution to journalArticle

Abstract

The use of TNF-a antagonists (infliximab, etanercept, adalimumab) has changed the course of many rheumatic diseases including rheumatoid arthritis (RA). Since their approval, some questions regarding their safety have been raised. Both acute and delayed reactions have been described. Methods. The aim of our work was to detect if there is a different incidence of hypersensitivity reactions infusion reactions to infliximab or injection site reactions with etanercept or adalimumab in atopic patients versus nonatopic patients. In 90 patients (82 females, 8 males) with rheumatoid arthritis we evaluated, during the first year of therapy with three different TNF-α blocking agents, total serum IgE (normal value

Original languageEnglish
Pages (from-to)333-336
Number of pages4
JournalClinical and Experimental Rheumatology
Volume27
Issue number2
Publication statusPublished - Mar 2009

Fingerprint

Rheumatoid Arthritis
Hypersensitivity
Rheumatic Diseases
Immunoglobulin E
Reference Values
Therapeutics
Safety
Injections
Incidence
Serum
Etanercept
Adalimumab
Infliximab

Keywords

  • Anti-TNF alpha
  • Atopy
  • Hypersensitivity reactions

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

@article{d2ed8835e0464ee78266d786ff740c02,
title = "Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-cL blocking agents in rheumatoid arthritis",
abstract = "The use of TNF-a antagonists (infliximab, etanercept, adalimumab) has changed the course of many rheumatic diseases including rheumatoid arthritis (RA). Since their approval, some questions regarding their safety have been raised. Both acute and delayed reactions have been described. Methods. The aim of our work was to detect if there is a different incidence of hypersensitivity reactions infusion reactions to infliximab or injection site reactions with etanercept or adalimumab in atopic patients versus nonatopic patients. In 90 patients (82 females, 8 males) with rheumatoid arthritis we evaluated, during the first year of therapy with three different TNF-α blocking agents, total serum IgE (normal value",
keywords = "Anti-TNF alpha, Atopy, Hypersensitivity reactions",
author = "M. Benucci and M. Manfredi and G. Saviola and P. Baiardi and P. Campi",
year = "2009",
month = "3",
language = "English",
volume = "27",
pages = "333--336",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "2",

}

TY - JOUR

T1 - Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-cL blocking agents in rheumatoid arthritis

AU - Benucci, M.

AU - Manfredi, M.

AU - Saviola, G.

AU - Baiardi, P.

AU - Campi, P.

PY - 2009/3

Y1 - 2009/3

N2 - The use of TNF-a antagonists (infliximab, etanercept, adalimumab) has changed the course of many rheumatic diseases including rheumatoid arthritis (RA). Since their approval, some questions regarding their safety have been raised. Both acute and delayed reactions have been described. Methods. The aim of our work was to detect if there is a different incidence of hypersensitivity reactions infusion reactions to infliximab or injection site reactions with etanercept or adalimumab in atopic patients versus nonatopic patients. In 90 patients (82 females, 8 males) with rheumatoid arthritis we evaluated, during the first year of therapy with three different TNF-α blocking agents, total serum IgE (normal value

AB - The use of TNF-a antagonists (infliximab, etanercept, adalimumab) has changed the course of many rheumatic diseases including rheumatoid arthritis (RA). Since their approval, some questions regarding their safety have been raised. Both acute and delayed reactions have been described. Methods. The aim of our work was to detect if there is a different incidence of hypersensitivity reactions infusion reactions to infliximab or injection site reactions with etanercept or adalimumab in atopic patients versus nonatopic patients. In 90 patients (82 females, 8 males) with rheumatoid arthritis we evaluated, during the first year of therapy with three different TNF-α blocking agents, total serum IgE (normal value

KW - Anti-TNF alpha

KW - Atopy

KW - Hypersensitivity reactions

UR - http://www.scopus.com/inward/record.url?scp=67249097204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67249097204&partnerID=8YFLogxK

M3 - Article

C2 - 19473578

AN - SCOPUS:67249097204

VL - 27

SP - 333

EP - 336

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 2

ER -